Neurotropin联合Celecoxib治疗膝关节骨性关节炎的疗效观察

Clinical observation of neurotropin combined with celecoxib in the treatment of knee osteoarthritis

目的观察Neurotropin联合Celecoxib治疗膝关节骨性关节炎(knee osteoarthritis,KOA)的疗效和安全性。方法采用随机、平行对照研究临床方法,将130例膝关节关节骨关节炎患者随机分为两组,对照组和试验组各为65例。对照组给予口服Celecoxib,实验组给予口服Celecoxib和Neurotropin,共治疗4周,停药后继续观察2周。采用Lequesne指数作为疗效评分标准,观察服药前后膝关节症状变化:包括休息痛、运动痛、压痛、肿胀、晨僵和行走能力的改善程度,记录治疗效果、不良反应及实验室生化指标等。结果治疗后4周,两组Lequesne总指数与治疗前相比,均明显下降。继续观察2周,两组都能维持原有的治疗效果。治疗后6周,试验组总有效率明显优于对照组(94%比88%)。安全性方面两组比较差异无统计学意义。结论 Neurotropin联合Celecoxib治疗KOA,能明显改善患者的临床症状,并不增加副反应,疗效优于单纯的Celecoxib治疗。

Objective To evaluate the therapeutic effects and safety of a combined therapy of neurotropin （ NTP ） and celecoxib in the treatment of knee osteoarthritis （ KOA ）. Methods A randomized and parallel-controlled clinical trial was performed in 130 patients with KOA, who were randomly divided into 2 groups. The patients in the control group only took celecoxib orally （ n=65 ）, and the patients in the experimental group took both NTP and celecoxib orally （ n=65 ）. All the patients were treated for 4 weeks, and then were observed for the next 2 weeks. According to Lequesne’s criteria, the improvement in knee joint symptoms were evaluated before and after the treatment, including knee pain at rest, at movement and at pressure, knee swelling, morning stiffness and walking ability. The therapeutic effects, adverse events and biochemical indexes were also recorded. Results The Lequesne’s total scores in both groups were obviously reduced after 4 weeks of treatment when compared with those before the treatment. The therapeutic effects in both groups were maintained for the next 2 weeks after the discontinuation of treatment. The total effective rate in the experimental group （ 94%） after 6 weeks of treatment was much higher than that in the control group （ 88%）. There were no statistically signiifcant differences in the safety between the 2 groups. Conclusions The combined therapy of NTP and celecoxib for KOA is signiifcantly more effective than the celecoxib alone. The clinical symptoms of the patients can be obviously improved, without new adverse events. {URL}： http：//d.g.wanfangdata.com.cn/Periodical_zggzlzz201404018.aspx